Jason Fieser, MD
Pulmonary Disease · Overland Park, KSNPI 1336241215
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.
Across 306 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$609
- Boehringer Ingelheim$397
- Regeneron Healthcare Solutions, Inc.$390
- Merck$312
- Mylan Specialty L.p.$310
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,695100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,059 |
| GSK | 34 | $609 |
| Boehringer Ingelheim | 20 | $397 |
| Regeneron Healthcare Solutions, Inc. | 13 | $390 |
| Merck | 16 | $312 |
| Mylan Specialty L.p. | 19 | $310 |
| Grifols USA, LLC | 12 | $249 |
| Sanofi | 12 | $243 |
| Jazz Pharmaceuticals Inc. | 11 | $239 |
| AbbVie(2 entities) | 11 | $217 |
| Insmed, Inc. | 11 | $191 |
| Genentech USA, Inc. | 10 | $141 |
| Electromed, Inc. | 8 | $126 |
| Harmony Biosciences LLC | 7 | $125 |
| United Therapeutics Corporation | 5 | $123 |
| Axsome Therapeutics, Inc. | 5 | $112 |
| Amgen | 6 | $109 |
| Sunovion Pharmaceuticals Inc. | 10 | $108 |
| Advanced Respiratory, Inc | 5 | $90 |
| Melinta Therapeutics, LLC | 4 | $53 |
| Philips North America LLC | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Baxter Healthcare | 2 | $41 |
| Viatris Specialty LLC | 2 | $40 |
| Novartis | 2 | $39 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $37 |
| Optinose US, Inc. | 1 | $28 |
| Resmed Corp | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Pfizer | 1 | $23 |
| Shire North American Group Inc | 2 | $22 |
| Eisai Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $11 |
How this compares
$5,706 in reported general payments places this provider in the 65th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $432,756 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 250 | $221,432 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 279 | $187,065 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 140 | $92,304 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $66,450 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $60,423 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 164 | $27,107 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $23,593 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $18,578 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 475 | $13,102 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 30 | $12,929 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $11,571 |
| Spiriva RespimatTiotropium Bromide | 12 | $10,969 |
| Spiriva HandihalerTiotropium Bromide | 12 | $9,837 |
| Wixela InhubFluticasone Propion/Salmeterol | 59 | $7,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $397 | $547,599205 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $609 | $492,513677 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,059 | $97,956135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Overland Park
- Brietta ForbesOverland Park$10K
- Mitchell TenerOverland Park$6K
- James KaplanOverland Park$4K
- Daniel BalmacedaOverland Park$3K
- Trenton NauserOverland Park$1K
- John NelsonOverland Park$1K
- Christine CookOverland Park$1K
- Scott EveloffOverland Park$903
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.